Fractyl Health (NASDAQ:GUTS) Coverage Initiated by Analysts at HC Wainwright

Key Points

• HC Wainwright has initiated coverage on Fractyl Health (NASDAQ:GUTS) with a "buy" rating and a target price of $9.00.
• Fractyl Health has recently faced challenges, reporting an EPS of ($0.53), missing estimates and exhibiting a negative return on equity of 584.35%.
• Multiple institutional investors, including Osaic Holdings and General Catalyst Group, have increased their stakes significantly in Fractyl Health, reflecting growing interest in the company.

HC Wainwright initiated coverage on shares of Fractyl Health (NASDAQ:GUTS - Free Report) in a research report sent to investors on Monday, MarketBeat reports. The brokerage issued a buy rating and a $9.00 target price on the stock. HC Wainwright also issued estimates for Fractyl Health's Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.41) EPS, FY2026 earnings at ($1.22) EPS, FY2027 earnings at ($1.32) EPS, FY2028 earnings at ($1.28) EPS and FY2029 earnings at ($1.36) EPS.

A number of other research firms also recently issued reports on GUTS. LADENBURG THALM/SH SH assumed coverage on shares of Fractyl Health in a research report on Thursday, August 28th. They set a "buy" rating and a $3.60 price target for the company. Canaccord Genuity Group lowered their target price on Fractyl Health from $12.00 to $6.00 and set a "buy" rating for the company in a research note on Thursday, August 14th. Four research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Fractyl Health presently has a consensus rating of "Buy" and an average price target of $7.15.

Fractyl Health Price Performance

GUTS traded up $0.00 during trading on Monday, reaching $0.99. The company's stock had a trading volume of 577,679 shares, compared to its average volume of 526,638. The company has a market cap of $49.74 million, a price-to-earnings ratio of -0.48 and a beta of 1.55. The company has a quick ratio of 1.22, a current ratio of 1.22 and a debt-to-equity ratio of 4.61. Fractyl Health has a 1 year low of $0.83 and a 1 year high of $3.48. The firm has a fifty day simple moving average of $1.27 and a two-hundred day simple moving average of $1.45.

Fractyl Health (NASDAQ:GUTS - Get Free Report) last released its earnings results on Tuesday, August 12th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.16). Fractyl Health had a negative net margin of 73,864.52% and a negative return on equity of 584.35%. As a group, analysts anticipate that Fractyl Health will post -1.61 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Catalyst Funds Management Pty Ltd purchased a new position in Fractyl Health during the second quarter valued at approximately $26,000. Jane Street Group LLC bought a new stake in Fractyl Health in the second quarter worth $31,000. Chicago Partners Investment Group LLC acquired a new position in Fractyl Health during the first quarter worth $37,000. HighTower Advisors LLC increased its holdings in shares of Fractyl Health by 57.9% during the 1st quarter. HighTower Advisors LLC now owns 40,921 shares of the company's stock worth $49,000 after purchasing an additional 15,000 shares during the period. Finally, Osaic Holdings Inc. raised its position in shares of Fractyl Health by 460.3% during the second quarter. Osaic Holdings Inc. now owns 59,645 shares of the company's stock valued at $97,000 after buying an additional 49,000 shares during the last quarter.

About Fractyl Health

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.